In episode 48 of Hims House, Jonathan Stern and Patrick Lester (Bayside) are joined by Saad Alam, founder & CEO of Hone Health. The discussion dives into Saad’s personal health journey and the founding of Hone Health during the pandemic. Saad discusses the company’s focus on hormonal health, weight loss, thyroid medications, and new longevity medications. Saad shares insights into diagnostics, the future of primary care, implications of the Meta ad privacy policy changes and FDA advertising crackdown, and the future of the telehealth industry.

00:43 Saad’s personal health journey

02:34 Hone’s products, revenue, competitors

04:29 Enclomiphene vs. clomiphene

09:07 Testosterone market and demographics

14:10 What longevity means

19:25 Lab testing and biomarkers

22:09 Why Hone hasn’t offered GLP-1s

25:14 “Everyone has a Chinese peptide dealer now”

33:53 Which peptides should Hims start with

35:38 Meta ads and the FDA crackdown on ads

40:43 Is primary care in trouble?

47:52 Why Saad is bullish on Hims

Get full access to Hims House at himshouse.substack.com/subscribe